Introduction
============

Lung cancer is the leading cause of cancer death globally, accounting for 18.20% of all cancer deaths. The incidence rate is ranked first in the global incidence of cancers, accounting for 12.70% of all cancer cases ([@b1-ol-0-0-10337]). According to statistics, among the number of lung cancer cases in Serbia of southeastern Europe, the incidence rates in men were higher than those of women and the mortality rates of male patients were four times higher than those of female patients. This may be due to the smoking habit in males ([@b2-ol-0-0-10337]). According to the histological type of lung cancer, it can be divided into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC accounts for most causes of lung cancer, according to statistics, NSCLC accounts for 80% of all patients with lung cancers ([@b3-ol-0-0-10337]). NSCLC has no obvious symptoms in the early stage, normally patients are already in the advanced stage when obvious clinical symptoms or physiological reactions occur. Some statistics have shown that most NSCLC patients are already in the advanced stage at the time of diagnosis ([@b4-ol-0-0-10337]). According to the pathological type of NSCLC, it is mainly classified into large cell carcinoma, squamous cell carcinoma and adenocarcinoma. Among them, adenocarcinoma and squamous cell lung cancer are the main types of cancers ([@b5-ol-0-0-10337]). Surgical resection is the main treatment method for NSCLC, however, patients with NSCLC have a higher recurrence rate ([@b6-ol-0-0-10337]). With the development of medical technology, chemotherapy has become more effective in the treatment of NSCLC. Although the prognosis of patients with NSCLC has improved it is affected by drug resistance. Moreover, the five-year survival rate of NSCLC patients is still less than 20% and seriously affects people\'s health ([@b7-ol-0-0-10337]). Therefore, we have to continue to find effective tumor markers to judge the prognosis of NSCLC clinically.

microRNA (miRNA) is an endogenous non-protein-encoded small RNA, located in eukaryotic cells and approximately 22 nt in length. Studies have shown that its expression has a certain impact on the occurrence, development, invasion, metastasis and prognosis of many malignant tumors, which has an important effect in inhibiting tumors or promoting tumor development ([@b8-ol-0-0-10337]). miRNA has a great significance in the diagnosis and treatment evaluation of NSCLC and can be used as a non-invasive biomarker for prognosis ([@b9-ol-0-0-10337]).

miR-21 is one of the miRNAs located on human chromosome 17q23.2 and with an abnormally high expression in many malignant tumors, also is a type of oncogene ([@b10-ol-0-0-10337]). Studies have shown that the growth and invasion of NSCLC cancer cells can be promoted by inhibiting the tumor suppressor phosphatase and tensin homolog deleted from chromosome 10 (PTEN). The expression levels of miR-21 were highly expressed in NSCLC patients and the expression of miR-21 was associated with TNM stages and distant metastasis in NSCLC patients ([@b11-ol-0-0-10337]). miR-155 is an important member of miRNA, the gene is located on chromosome 21 and it was processed by non-protein-encoded transcripts of B cell fusion cluster genes ([@b12-ol-0-0-10337]). miR-155 promotes the growth and development of tumor cells by regulating a variety of cancer-promoting pathways and has a high expression in a variety of malignancies ([@b13-ol-0-0-10337]). Studies have shown that miR-155 was highly expressed in NSCLC and induces the proliferation and invasion of NSCLC cancer cells by directly inhibiting the programmed cell death gene 4 ([@b14-ol-0-0-10337]).

There are few studies on the high expression of miR-155 and miR-21 and the recurrence or metastasis of NSCLC patients. This research investigated the expression levels of serum miR-155 and miR-21 in patients with recurrence or metastasis of NSCLC. We also explored the relationship between the high expression of miR-155 and miR-21 and the recurrence or metastasis of NSCLC in order to provide clinical references.

Materials and methods
=====================

### General information

Retrospective analysis of the clinical information of 180 patients with NSCLC admitted to Daqing Oil Field General Hospital (Daqing, China) from February 2012 to March 2015 were carried out. These patients were the research group. There were 124 cases of males and 56 cases of females, with an average age 66.37±7.21 years. Physical examination information of 88 normal medical examinees was selected during the same period of time, and set as the control group. There were 63 cases of males and 25 cases of females, average age 64.98±7.23 years. Sixty-eight patients in the research group were newly diagnosed with NSCLC, and were set as the newly diagnosed group and there were 46 cases of males and 22 cases of females. In addition, 112 patients with recurrence or metastasis of NSCLC were the recurrence group, there were 78 cases of males and 34 cases of females.

This investigation was approved by the Ethics Committee of Daqing Oil Field General Hospital, patients or their family members signed the informed consent form.

### Inclusion and exclusion criteria

Inclusion criteria: Age ≥18 years; no other hereditary diseases; patients with a complete clinical medical records or physical examination information; included were only patients who were treated in Daqing Oil Field General Hospital; no deaths occurred during the treatment and the patients have been discharged. Exclusion criteria: Patients with cardiovascular disease, patients with second primary tumors; patients who had taken antibiotics in the last three months; combined with severe liver and kidney dysfunction; combined with other connective tissue diseases, endocrine and metabolic diseases; and patients with a history of mental illness or family history of mental illness.

### Main reagents and instruments

PCR amplifier (manufacturer: Tianjin Jinside Biotechnology Co., Ltd., Tianjin, China, model: ABI 2700); TRIzol extractant (manufacturer: Beijing Suo Laibao Technology Co., Ltd., Beijing, China, batch number: 15596-026); high-speed centrifuge (manufacturer: Anhui Zhongke Zhongjia Scientific Instrument Co., Ltd., Hefei, China, model: HC-2518R); reverse transcription RT kit (manufacturer: Shanghai Jiemei Gene Pharmaceutical Technology Co., Ltd., Shanghai, China, batch number: GMS20020.4); RT-qPCR kit (manufacturer: Shanghai Chuangye Biotechnology Co., Ltd., Shanghai, China, article number: ZY131042) were used in the present study. The miR-155 and miR-21 and the internal reference β-actin primer sequences were designed and produced by Suzhou Yuxun Biotechnology Co., Ltd. Suzhou, China ([Table I](#tI-ol-0-0-10337){ref-type="table"}).

### Collection of serum

The operation steps were all carried out in a sterile environment, 6 ml of the external elbow venous blood was extracted in the morning after all the experimental subjects had fasted for 8 h. Blood was then placed in a vacuum blood collection tube for 25 min, the serum was separated in a centrifuge at 3,000 × g at 22°C for approximately 15--20 min. After separation, 350 µl of the supernatant was placed in an EP tube. After being placed in liquid nitrogen for quick freezing, it was stored at −80°C.

### Extraction of total RNA and synthesis of cDNA

The RNA was extracted using TRIzol, serum was taken from the refrigerator, 1.05 ml TRIzol was added and agitated for 5 min. The mixture was kept at room temperature for 10 min and 600 µl of chloroform was added after the cells were completely lysed. The mixture was mixed until the solution was emulsified and milky white after which it was left to stand for 5 min, following centrifugation at 800 × g for 15 min at 4°C. The top colorless supernatant was carefully absorbed into the centrifuge tube using a pipette, an equal volume of isopropanol was added and centrifuged for further 10 min. After centrifugation, the precipitate was washed by adding 1 ml of 75% ethanol to obtain RNA. The RNA integrity was tested by using 1% agarose gel electrophoresis. Then a qualified RNA sample was selected for cDNA synthesis, and reverse transcribed cDNA using 1 µl of total RNA, the reaction was carried out under reaction conditions of 42°C for 55 min.

### Detection of the expression levels of miR-155 and miR-21

The expression levels of miR-155 and miR-21 were detected by RT-qPCR and the reaction system of 20 µl volume. First, pre-denaturation at 95°C for 15 min, then denaturation at 94°C for 15 sec, annealing at 56°C for 30 sec and extension at 70°C for 30 sec, and repetition of the 40 cycles. The experiment was repeated 3 times and completed within 30 days. The standard curve was based on the standard concentration and the average value of the cycle depreciation corresponding to each concentration. According to the standard curve, the instrument automatically calculates the copy number/ml of miR-155, miR-21 and β-actin in serum. In addition, the ratio of miR-155, miR-21 and β-actin was used as the expression level of miR-155 and miR-21.

### Follow up for the research group

After the treatment, all NSCLC patients discharged from the hospital were followed up once every month for 36 months, mainly by telephone. Home visit survey or consultation with relatives were conducted for patients who had poor telephone follow-ups and elderly patients or those with poor physical fitness. This ensured the accurate recording of deaths in the research group.

### Statistical analysis

Statistical analysis was performed using SPSS19.0 \[Yiyun (Shanghai) Information Technology Co., Ltd., Shanghai, China\] and measurement data was expressed as mean ± standard deviation (mean ± SD). The t-test was used to compare the measurement data between all the groups and the Chi-square test was used to compare the countable data between the groups. Survival analysis was performed using Kaplan-Meier and the log-rank test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### General baseline information

Factors including age, sex, body mass index, heart rate, smoking status, fasting blood glucose level, hemoglobin (Hb) value, red blood cell (RBC) value, and platelet (PLT) value between the research and control groups were compared. The difference between the groups was not statistically significant (P\>0.05) ([Table II](#tII-ol-0-0-10337){ref-type="table"}).

Expression levels of serum miR-155 and miR-21 between the research and control groups. The experiment results showed that the expression level of miR-21 in the research group was 7.13±3.76, which was higher than that in the control group (1.45±0.62) and the difference between two groups was statistically significant (t=14.060, P\<0.01). The expression level of miR-155 in the research group was 6.34±3.93, which was higher than that in the control group (1.32±0.52). The difference between two groups was statistically significant (t=11.920, P\<0.01) ([Fig. 1](#f1-ol-0-0-10337){ref-type="fig"}).

### Clinical information in the subgroup of the research group

Factors including age, sex, body mass index, smoking status, tumor diameter, differentiation, histological type, and TNM stage between the recurrence group and the newly diagnosed group were compared. The difference between the groups was not statistically significant (P\>0.05) ([Table III](#tIII-ol-0-0-10337){ref-type="table"}).

### Expression of serum miR-155 and miR-21 in the subgroup of the research group

The results of the experiment showed that the expression level of miR-21 in the recurrence group was 8.18±2.71, which was higher than that in the newly diagnosed group (5.33±1.96). The difference between the groups was statistically significant (t=7.552, P\<0.01). The expression level of miR-155 in the recurrence group was 7.69±2.58, which was higher than that in the newly diagnosed group (4.97±2.56). The difference between the groups was statistically significant (P\<0.05) ([Fig. 2](#f2-ol-0-0-10337){ref-type="fig"}).

### Subgroup of the research group

A 36-month fllow-up was conducted to both the recurrence group and the newly diagnosed group. At follow-up, 103 cases of patients died in the recurrence group, with a median survival time of 19 months and a mortality rate of 91.96%. In addition, 39 patients died in the newly diagnosed group, the median survival time was 28 months and the mortality rate was 57.35%. The difference between two groups was statistically significant (χ^2^=9.705, P\<0.01) ([Fig. 3](#f3-ol-0-0-10337){ref-type="fig"}).

Discussion
==========

Lung cancer is the most malignant tumor with the highest morbidity and mortality rate in the world ([@b15-ol-0-0-10337]). Assessment of the prognosis of NSCLC is currently carried out using tissue cytological examination. However, these are intrusive inspection methods and often require obtaining tissues or cells, via lung puncture, biopsy or bronchoscopy. These methods are not readily accepted by patients due to inconvenience and trauma ([@b16-ol-0-0-10337]). In addition, a non-invasive, easy-to-use and highly accurate biomarker is required to assess the prognosis of NSCLC clinically.

miR-21 and miR-155 both have an important effect in the occurrence and development of lung cancer. Studies have shown that miR-155 has considerable regulatory effect in the proliferation, differentiation and growth of T cells ([@b17-ol-0-0-10337]). miR-21 causes signal transduction and activation on transcriptional activator 3, which increases the vascular endothelial growth factor levels in recipient cells. This indirectly leads to malignant transformation of human bronchial epithelioid cells ([@b18-ol-0-0-10337]). The expression levels of miR-21 and miR-155 are elevated in various solid malignant tumors such as breast cancer, B cell lymphoma, lung cancer and colon cancer. Moreover, decreased expression levels of miR-21 and miR-155 can induce apoptosis and inhibit the proliferation and invasion of cells ([@b19-ol-0-0-10337]).

Xue *et al* ([@b20-ol-0-0-10337]) reported that the expression levels of miR-21 and miR-155 are increased in patients with NSCLC. In addition, silencing miR-21 and miR-155 can effectively inhibit the progression of NSCLC in the animals of xenotransplantation. Furthermore, combined inhibition of miR-21 and miR-155 can effectively improve the therapeutic effect of NSCLC, which is similar to our research results. We studied the expression levels of miR-21 and miR-155 in the serum between normal and NSCLC patients. It was found that miR-21 and miR-155 were highly expressed in the serum of NSCLC patients, which were higher than those in the normal patients (P\<0.05). We further investigated the expression levels of miR-21 and miR-155 of the serum in patients with recurrence of NSCLC or metastasis and found that the expression levels of miR-21 and miR-155 with recurrence or metastatic NSCLC were higher than those in the newly diagnosed patients with NSCLC (P\<0.05). The results of Yang *et al* ([@b21-ol-0-0-10337]) were similar to our results, they found that the high expression levels of miR-21 and miR-155 in the post-operative recurrence and metastasis of patients with NSCLC were higher than those of patients with low expression levels. However, the survival rate was lower than that of patients with a low expression level. We conducted a 36-month follow up in the newly diagnosed patients and NSCLC patients with recurrence or metastasis. The mortality rate of the NSCLC with recurrence or metastasis was 91.96%, the median survival time was 19 months and the initial diagnosis of NSCLC patients had a mortality rate of 57.35% and the median survival time was 28 months. The difference in survival rate between the two groups was statistically significant (P\<0.05). Moreover, patients with recurrence or metastasis of NSCLC had a poor survival rate. The results of this investigation are similar to those of Lashiotaki *et al* ([@b22-ol-0-0-10337]) who considered that the high expression of miR-21 and miR-155 may reduce the overall survival and recurrence-free survival rate in patients with NSCLC. This can lead to poor prognosis in patients with NSCLC and reduces patient survival time. Donnem *et al* ([@b23-ol-0-0-10337]) reported that highly expressed miR-155 has a significant negative impact on the survival rates and prognosis of NSCLC and it is an independent prognostic factor for NSCLC. Gironella *et al* ([@b24-ol-0-0-10337]) considered that miR-155 is abnormally highly expressed in pancreatic cancer. It may be caused by inhibition of the mRNA function of TP53INP1 and resulted in a decrease in its expression level. Therefore, it inhibits tumor cell apoptosis and promotes tumor cell proliferation. In addition, Meng *et al* ([@b25-ol-0-0-10337]) believe that the expression level of PTEN can be increased by inhibiting the expression of miR-21 in liver cancer cells and therefore the proliferation and metastasis of tumors were inhibited. The PTEN gene may be impacted by miR-21 and could affect the metastasis and recurrence in tumors. This indicates that high expression of miR-21 and miR-155 is associated with recurrence and metastasis of tumors.

Retrospective case analysis was used during this study and the pathology was strictly selected according to the inclusion and exclusion criteria. The basic patient information investigation, clinical examination, and special inspection were strictly recorded and organized. Moreover, a 36-month follow-up was conducted in the NSCLC patients, this accurately recorded the patient death rate and obtained a reliable result.

miR-21 and miR-155 were highly expressed in the serum of patients with NSCLC, and the expression levels of serum in NSCLC patients with recurrence and metastasis was even higher. Highly expressed miR-21 and miR-155 were associated with recurrence and metastasis in patients with NSCLC reducing survival rate and affecting prognosis of patients.
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###### 

miR-155 and miR-21 and internal reference β-actin primer sequences.

  Gene names   Upstream primer                 Downstream primer
  ------------ ------------------------------- --------------------------------
  *miR-21*     5′-TGCGCTAGCTTATCAGACTGAT-3′    5′-CCAGTGCAGGGTCCGAGGTATT-3′
  *miR-155*    5′-CTGTAT-CAAAAGGCCAACTGAA-3′   5′-GTGTCTATCCT-TATGAATCGCCA-3′
  *β-actin*    5′-AGCGGGAAATCGTGCGTGACA-3′     5′-GTG-GACTTGGGAGAGGACTGG-3′

###### 

Comparison of baseline information between the research group and the control group \[n (%)\] (mean ± SD).

  Characteristics                  Research group (n=180)   Control group (n=88)   χ^2^/t value   P-value
  -------------------------------- ------------------------ ---------------------- -------------- ---------
  Age (years)                      66.37±7.21               64.98±7.23             1.481          0.140
  Sex                                                                              0.205          0.674
    Male                           124 (68.89)              63 (71.59)                            
    Female                           56 (31.11)             25 (28.41)                            
  BMI (kg/m^2^)                                                                    0.164          0.755
    \<24                           141 (78.33)              67 (76.14)                            
    ≥24                              39 (21.67)             21 (23.86)                            
  Smoking status                                                                   1.636          0.240
    Smoker                         136 (75.56)              60 (68.18)                            
    Non-smoker                       44 (24.44)             28 (31.82)                            
  Heart rate (times/min)                                                           0.642          0.503
    \<60                           15 (8.33)                10 (11.36)                            
    ≥60                            165 (91.67)              78 (88.64)                            
  Fasting blood glucose (mmol/l)   4.48±0.62                4.53±0.56              0.640          0.523
  Hb (g/l)                         115.24±14.26             117.25±13.63           1.099          0.273
  RBC (×10^12^/l)                  4.51±0.26                4.55±0.35              1.051          0.294
  PLT (×10^9^/l)                   224.24±36.73             218.99±55.36           0.924          0.357

###### 

Comparison of clinical information between the recurrence group and the newly diagnosed group \[n (%)\].

  Characteristics             Recurrence group (n=112)   Newly diagnosed group (n=68)   χ^2^ value   P-value
  --------------------------- -------------------------- ------------------------------ ------------ ---------
  Age (years)                                                                           0.342        0.631
    \<65                      38 (33.93)                 26 (38.24)                                  
    ≥65                       74 (66.07)                 42 (61.76)                                  
  Sex                                                                                   0.079        0.868
    Male                      78 (69.64)                 46 (67.65)                                  
    Female                    34 (30.36)                 22 (32.35)                                  
  BMI (kg/m^2^)                                                                         0.418        0.579
    \<24                      86 (76.79)                 55 (80.88)                                  
    ≥24                       26 (23.21)                 13 (19.12)                                  
  Smoking status                                                                        0.880        0.377
    Smoker                    82 (73.21)                 54 (79.41)                                  
    Non-smoker                30 (26.79)                 14 (20.59)                                  
  Tumor diameter                                                                        0.116        0.752
    \<5 cm                    40 (35.71)                 26 (38.24)                                  
    ≥5 cm                     72 (64.29)                 42 (61.76)                                  
  Histological type                                                                     0.095        0.878
    Squamous cell carcinoma   57 (50.89)                 33 (48.53)                                  
    Adenocarcinoma            55 (49.11)                 35 (51.47)                                  
  Differentiation                                                                       0.702        0.482
    Mid and low               81 (72.32)                 53 (77.94)                                  
    High                      31 (27.68)                 15 (22.06)                                  
  TNM stages                                                                            0.142        0.755
    I--II                     46 (41.07)                 26 (38.24)                                  
    III--IV                   66 (58.93)                 42 (61.76)                                  
